Advertisement

Quality of life after the initial treatment of atrial fibrillation with cryoablation versus drug therapy

Published:October 15, 2021DOI:https://doi.org/10.1016/j.hrthm.2021.10.009

      Background

      The STOP AF First trial recently demonstrated that initial treatment with cryoballoon ablation (CBA) is safe and superior to antiarrhythmic drug (AAD) therapy for preventing atrial arrhythmia recurrence in patients with symptomatic atrial fibrillation (AF).

      Objective

      The purpose of this study was to evaluate the change in quality of life (QoL) and symptoms after first-line CBA vs AAD therapy.

      Methods

      Patients with symptomatic AF not previously receiving rhythm control therapy were randomized to AAD (class I or III) or CBA (Arctic Front Advance, Medtronic, Mounds View, MN). QoL was evaluated at baseline and at 6 and 12 months by using the Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) and the European Quality of Life–5 Dimensions questionnaires. A review of AF-associated symptoms was conducted at baseline and at 1, 3, 6, and 12 months.

      Results

      In total, 203 subjects received either CBA (n = 104 [51.2%]) or AAD therapy (n = 99 [48.8%]). Improvements in the AFEQT summary and subscale scores were significantly larger with CBA than with AAD therapy at 6 and 12 months (P < .02 for all). Clinically meaningful improvement (>5 points) in the AFEQT summary score from baseline to 12 months was observed in 96.0% (100) of patients in the CBA arm vs 72.2% (71) of patients in the AAD arm (P < .001). No significant between-group differences were observed in the change in the European Quality of Life–5 Dimensions index or visual analog scale scores. Overall, 54.4% (57) of the CBA group vs 29.7% (29) of the AAD group reported no AF-specific symptom recurrence after a 90-day blanking period (P = .0005).

      Conclusion

      First-line CBA vs AAD therapy is associated with larger improvements in AF-specific QoL and a higher rate of symptom resolution.

      Graphical abstract

      Keywords

      To read this article in full you will need to make a payment
      Subscribe to Heart Rhythm
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Stridsman M.
        • Stromberg A.
        • Hendriks J.
        • Walfridsson U.
        Patients’ experiences of living with atrial fibrillation: a mixed methods study.
        Cardiol Res Pract. 2019; 2019: 6590358
        • Freeman J.V.
        • Simon D.N.
        • Go A.S.
        • et al.
        Association between atrial fibrillation symptoms, quality of life, and patient outcomes: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF).
        Circ Cardiovasc Qual Outcomes. 2015; 8: 393-402
        • Steinberg B.A.
        • Kim S.
        • Fonarow G.C.
        • et al.
        Drivers of hospitalization for patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF).
        Am Heart J. 2014; 167: 735-742.e732
        • Hindricks G.
        • Potpara T.
        • Dagres N.
        • et al.
        2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS).
        Eur Heart J. 2021; 42: 373-498
        • January C.T.
        • Wann L.S.
        • Alpert J.S.
        • et al.
        2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.
        Circulation. 2014; 130: e199-e267
        • Calkins H.
        • Hindricks G.
        • Cappato R.
        • et al.
        2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation.
        Europace. 2018; 20: e1-e160
        • Andrade J.G.
        • Wells G.A.
        • Deyell M.W.
        • et al.
        Cryoablation or drug therapy for initial treatment of atrial fibrillation.
        N Engl J Med. 2021; 384: 305-315
        • Wazni O.M.
        • Dandamudi G.
        • Sood N.
        • et al.
        Cryoballoon ablation as initial therapy for atrial fibrillation.
        N Engl J Med. 2021; 384: 316-324
        • Kuniss M.
        • Pavlovic N.
        • Velagic V.
        • et al.
        Cryoballoon ablation vs. antiarrhythmic drugs: first-line therapy for patients with paroxysmal atrial fibrillation.
        Europace. 2021; 23: 1033-1041
        • Holmes D.N.
        • Piccini J.P.
        • Allen L.A.
        • et al.
        Defining clinically important difference in the Atrial Fibrillation Effect on Quality-of-Life Score.
        Circ Cardiovasc Qual Outcomes. 2019; 12e005358
        • Dorian P.
        • Burk C.
        • Mullin C.M.
        • et al.
        Interpreting changes in quality of life in atrial fibrillation: how much change is meaningful?.
        Am Heart J. 2013; 166: 381-387.e388
        • Aliot E.
        • Botto G.L.
        • Crijns H.J.
        • Kirchhof P.
        Quality of life in patients with atrial fibrillation: how to assess it and how to improve it.
        Europace. 2014; 16: 787-796
        • Spertus J.
        • Dorian P.
        • Bubien R.
        • et al.
        Development and validation of the Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) Questionnaire in patients with atrial fibrillation.
        Circ Arrhythm Electrophysiol. 2011; 4: 15-25
        • Verma A.
        • Champagne J.
        • Sapp J.
        • et al.
        Discerning the incidence of symptomatic and asymptomatic episodes of atrial fibrillation before and after catheter ablation (DISCERN AF): a prospective, multicenter study.
        JAMA Intern Med. 2013; 173: 149-156
        • Reynolds M.R.
        • Ellis E.
        • Zimetbaum P.
        Quality of life in atrial fibrillation: measurement tools and impact of interventions.
        J Cardiovasc Electrophysiol. 2008; 19: 762-768
        • Cosedis Nielsen J.
        • Johannessen A.
        • Raatikainen P.
        • et al.
        Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.
        N Engl J Med. 2012; 367: 1587-1595
        • Wazni O.M.
        • Marrouche N.F.
        • Martin D.O.
        • et al.
        Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial.
        JAMA. 2005; 293: 2634-2640
        • Morillo C.A.
        • Verma A.
        • Connolly S.J.
        • et al.
        Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial.
        JAMA. 2014; 311: 692-700
        • Andrade J.G.
        • Macle L.
        • Verma A.
        • et al.
        Quality of life and health care utilization in the CIRCA-DOSE Study.
        JACC Clin Electrophysiol. 2020; 6: 935-944
        • Kuck K.H.
        • Lebedev D.S.
        • Mikhaylov E.N.
        • et al.
        Catheter ablation or medical therapy to delay progression of atrial fibrillation: the randomized controlled atrial fibrillation progression trial (ATTEST).
        Europace. 2021; 23: 362-369